Blodomloppet i en nervcell. Enligt undersökningar av den polske forskaren
Adamkiewicz försörjes varje nervcell av en artär (röd), som träder till cellen vinkelrätt mot densamma (till vänster på bilden). Denna vidgar sig sedan så att cellen på alla sidor ligger kringfluten av blodströmmen, som en ö i en flod. Mittemot artärens inträdesställe flyter blodet från cellen in i en ven, som blir allt tunnare (till höger på bilden). Från det omgivande blodet tränga syre- och näringsmolekylerna (röda punkter) in i cellens plasma. Kolsyra och avfallsprodukterna (blå punkter) samlas omkring kärnan i cellens mitt och flyta därifrån i en ven (blå) genom plasman och cellväggen utåt.
Från Fritz Kahn: Människan del IV, Albert Bonniers Förlag, Stockholm 1930 Översatt till svenska av Professor Ivar Broman och Docent Sture A. Siwe
(Ivar Broman var professor i anatomi i Lund, far till den kände kompositören och musikkritikern Sten Broman.)
A
CKNOWLEDGEMENTSAll participants in the studies, the patients as well as the staff in the different facilities, for their kind and generous participation and co-operation, allowing me to conduct this thesis.
Professor Torbjörn Nilsson, my supervisor and friend for all the support and introducing me in the scientific thinking. You have been necessary for this project. But we have more to science to “bake off” from our material and I look forward to further collaboration.
Professor Lars-Olof Wahlund, co-supervisor, you were indispensable discussing the complex world of dementia.
Professor Kurt Boman helped me through the maze of fibrinolysis.
Anna Böttiger, my co-author, who set up most of the genetical analyses included in this thesis.
Lovisa Olsson, for partnership in setting up and collecting the biobanks of the AS and DGM cohorts, and for the chemical analyses.
Professor emerita Henny Olsson, who introduced me to the importance of humor in healthcare and for helpful advice in the beginning of this project.
Lena Ek, Sari Hallinen Wilén and Malin Bäckman, psychologists at the Department of Geriatrics, for their help with the neuropsychological evaluations. Gunilla Forsberg, study nurse at the Department of Geriatrics, for help in solving the practical issues around this clinical research project.
Wanja Schwartz Hall, study nurse at the Department of Geriatrics, for help with administrating the MMSE and CDT test in the Active Seniors study.
Professor Matti Viitanen, for kind support and fair criticism in my mid-term evaluation.
Associate professor Björn Regland, for inspiring and enthusiastic discussions and for constructive criticism in my mid-term evaluation.
Dr Katarina Nägga, for taking your time and giving me strength during my mid- term evaluation.
Associate professor Peter Appelros, my former colleague and friend for your support in different phases of my work with this thesis.
Drs Lars Breimer and Ian Jones, colleagues and friends at the Department of Clinical Chemistry, for your valuable comments on the manuscript and for language revision.
My chief, Riitta Varelius, head of Department of Geriatrics, Örebro University Hospital, for your support. You made it possible to combine my PhD studies with my work as consultant in the department.
My colleagues in the Department of Geriatrics who made the Department function despite the strained situation with scarcity of colleagues.
The staff at the Medical Library, Örebro University Hospital for excellent help and assistance.
This thesis was financially supported by grants from Örebro University Hospital, Nyckelfonden, Örebro County Council, Örebro University, and Novartis, Sweden AB.
Our three sons, Anders, Fredrik and Niklas for help in creating the database the DGM study was based on.
Louise, my first and so far, only grandchild. It is always so relieving when your laughter sounds, the research linked problems becomes pushed in the background and the “real world” becomes real, again.
Last, but definitely not least, I want to thank my beloved wife, Lilian, without whom this research wouldn’t have become true. You supported me already when I began as a medical student. You have with your enormous patience and positive thinking done miracles to me and to our family.
R
EFERENCES1. Addison, T., Anemia: Disease of the suprarenal capsules. London Med Gaz, 1849;43:517-518.
2. Rorsman, B., O. Hagnell, and J. Lanke, Prevalence and incidence of senile and multi-infarct dementia in the Lundby Study: a comparison between the time periods 1947-1957 and 1957-1972. Neuropsychobiology, 1986;15:122-129.
3. Fratiglioni, L., D. De Ronchi, and H. Aguero-Torres, Worldwide prevalence and incidence of dementia. Drugs Aging, 1999;15:365-375. 4. Brookmeyer, R., S. Gray, and C. Kawas, Projections of Alzheimer's disease
in the United States and the public health impact of delaying disease onset. Am J Public Health, 1998;88:1337-1342.
5. World population ageing: 1950-2050. 2002, Department of economic and social affairs population division: United Nations: From: http://www.un.org/esa/population/publications/worldageing19502050/ Accessed February 3, 2008.
6. Fratiglioni, L., M. Viitanen, E. von Strauss, V. Tontodonati, A. Herlitz, and B. Winblad, Very old women at highest risk of dementia and Alzheimer's disease: incidence data from the Kungsholmen Project, Stockholm. Neurology, 1997;48:132-138.
7. Lowin, A., M. Knapp, and P. McCrone, Alzheimer's disease in the UK: comparative evidence on cost of illness and volume of health services research funding. Int J Geriatr Psychiatry, 2001;16:1143-1148.
8. Sicras, A., J. Rejas, S. Arco, E. Flores, G. Ortega, A. Esparcia, A. Suarez, and M.J. Gordillo, Prevalence, resource utilization and costs of vascular dementia compared to Alzheimer's dementia in a population setting. Dement Geriatr Cogn Disord, 2005;19:305-315.
9. 10 Leading Causes of Death in the U.S., 2004. 2009: From: http://www.infoplease.com/ipa/A0005110.html/ Accessed June 21, 2009. 10. Breteler, M.M., A. Ott, and A. Hofman, The new epidemic: frequency of
dementia in the Rotterdam Study. Haemostasis, 1998;28:117-123.
11. Mann, D.M., T. Iwatsubo, S.M. Pickering-Brown, F. Owen, T.C. Saido, and R.H. Perry, Preferential deposition of amyloid beta protein (Abeta) in the form Abeta40 in Alzheimer's disease is associated with a gene dosage effect of the apolipoprotein E E4 allele. Neurosci Lett, 1997;221:81-84. 12. Fratiglioni, L., Epidemiology. In: Health Economics of Dementia, ed. A.
Wimo, et al. 1998, John Wiley & Sons: London. 13-31.
13. Peters, R., J. Peters, J. Warner, N. Beckett, and C. Bulpitt, Alcohol, dementia and cognitive decline in the elderly: a systematic review. Age Ageing, 2008;37:505-512.
14. Kivipelto, M., S. Rovio, T. Ngandu, I. Kareholt, M. Eskelinen, B. Winblad, V. Hachinski, A. Cedazo-Minguez, H. Soininen, J. Tuomilehto, and A. Nissinen, Apolipoprotein E epsilon4 Magnifies Lifestyle Risks for Dementia: A Population Based Study. J Cell Mol Med, 2008;12:2762- 2771.
15. Mehlig, K., I. Skoog, X. Guo, M. Schutze, D. Gustafson, M. Waern, S. Ostling, C. Bjorkelund, and L. Lissner, Alcoholic beverages and incidence
of dementia: 34-year follow-up of the prospective population study of women in Goteborg. Am J Epidemiol, 2008;167:684-691.
16. Ferreira, P.C., A. Piai Kde, A.M. Takayanagui, and S.I. Segura-Munoz, Aluminum as a risk factor for Alzheimer's disease. Rev Lat Am Enfermagem, 2008;16:151-157.
17. Gupta, V.B., S. Anitha, M.L. Hegde, L. Zecca, R.M. Garruto, R. Ravid, S.K. Shankar, R. Stein, P. Shanmugavelu, and K.S. Jagannatha Rao, Aluminium in Alzheimer's disease: are we still at a crossroad? Cell Mol Life Sci, 2005;62:143-158.
18. Zhu, L., L. Fratiglioni, Z. Guo, H. Basun, E.H. Corder, B. Winblad, and M. Viitanen, Incidence of dementia in relation to stroke and the apolipoprotein E epsilon4 allele in the very old. Findings from a population-based longitudinal study. Stroke, 2000;31:53-60.
19. Breteler, M.M., M.L. Bots, A. Ott, and A. Hofman, Risk factors for vascular disease and dementia. Haemostasis, 1998;28:167-173.
20. Atti, A.R., K. Palmer, S. Volpato, B. Winblad, D. De Ronchi, and L. Fratiglioni, Late-life body mass index and dementia incidence: nine-year follow-up data from the Kungsholmen Project. J Am Geriatr Soc, 2008;56:111-116.
21. Kivipelto, M., E.L. Helkala, M.P. Laakso, T. Hanninen, M. Hallikainen, K. Alhainen, H. Soininen, J. Tuomilehto, and A. Nissinen, Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ, 2001;322:1447-1451.
22. Hartmann, T., J. Kuchenbecker, and M.O. Grimm, Alzheimer's disease: the lipid connection. J Neurochem, 2007;103 Suppl 1:159-170.
23. Henon, H., I. Durieu, D. Guerouaou, F. Lebert, F. Pasquier, and D. Leys, Poststroke dementia: incidence and relationship to prestroke cognitive decline. Neurology, 2001;57:1216-1222.
24. Haan, M.N., J.W. Miller, A.E. Aiello, R.A. Whitmer, W.J. Jagust, D.M. Mungas, L.H. Allen, and R. Green, Homocysteine, B vitamins, and the incidence of dementia and cognitive impairment: results from the Sacramento Area Latino Study on Aging. Am J Clin Nutr, 2007;85:511- 517.
25. Seshadri, S., Elevated plasma homocysteine levels: Risk factor or risk marker for the development of dementia and Alzheimer's disease? J Alzheimers Dis, 2006;9:393-398.
26. Ravaglia, G., P. Forti, F. Maioli, M. Martelli, L. Servadei, N. Brunetti, E. Porcellini, and F. Licastro, Homocysteine and folate as risk factors for dementia and Alzheimer disease. Am J Clin Nutr, 2005;82:636-643. 27. Seshadri, S., A. Beiser, J. Selhub, P.F. Jacques, I.H. Rosenberg, R.B.
D'Agostino, P.W. Wilson, and P.A. Wolf, Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med, 2002;346:476- 483.
28. Fratiglioni, L., E. von Strauss, and B. Winblad, Åldrandets epidemiologi med fokus på fysisk och mental funktionsförmåga. Läkartidningen, 2001;98:552-558.
29. Reitz, C., T. den Heijer, C. van Duijn, A. Hofman, and M.M. Breteler, Relation between smoking and risk of dementia and Alzheimer disease: the Rotterdam Study. Neurology, 2007;69:998-1005.
30. Skoog, I., Hypertension and cognition. Int Psychogeriatr, 2003;15 Suppl 1:139-146.
31. Fratiglioni, L., H.X. Wang, K. Ericsson, M. Maytan, and B. Winblad, Influence of social network on occurrence of dementia: a community- based longitudinal study. Lancet, 2000;355:1315-1319.
32. Alzheimer, A., R.A. Stelzmann, H.N. Schnitzlein, and F.R. Murtagh, An English translation of Alzheimer's 1907 paper, "Über eine eigenartige Erkankung der Hirnrinde". Clin Anat, 1995;8:429-431.
33. Maurer, K., S. Volk, and H. Gerbaldo, Auguste D and Alzheimer's disease. Lancet, 1997;349:1546-1549.
34. Graeber, M.B., S. Kosel, E. Grasbon-Frodl, H.J. Moller, and P. Mehraein, Histopathology and APOE genotype of the first Alzheimer disease patient, Auguste D. Neurogenetics, 1998;1:223-228.
35. Goedert, M., Oskar Fischer and the study of dementia. Brain, 2008;132:1102-1111.
36. Armbrustmacher, V.W., Pathology of dementia. Pathol Annu, 1979;14 Pt 1:145-173.
37. Aguero-Torres, H., M. Kivipelto, and E. von Strauss, Rethinking the Dementia Diagnoses in a Population-Based Study: What Is Alzheimer's Disease and What Is Vascular Dementia?. A Study from the Kungsholmen Project. Dement Geriatr Cogn Disord, 2006;22:244-249.
38. Skoog, I., Vascular aspects in Alzheimer's disease. J Neural Transm Suppl, 2000;59:37-43.
39. Knopman, D.S., Dementia and cerebrovascular disease. Mayo Clin Proc, 2006;81:223-230.
40. Cechetto, D.F., V. Hachinski, and S.N. Whitehead, Vascular risk factors and Alzheimer's disease. Expert Rev Neurother, 2008;8:743-750.
41. Purnell, C., S. Gao, C.M. Callahan, and H.C. Hendrie, Cardiovascular Risk Factors and Incident Alzheimer Disease: A Systematic Review of the Literature. Alzheimer Dis Assoc Disord, 2009;23:1-10.
42. Gilman, S., M. Koller, R.S. Black, L. Jenkins, S.G. Griffith, N.C. Fox, L. Eisner, L. Kirby, M.B. Rovira, F. Forette, and J.M. Orgogozo, Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology, 2005;64:1553-1562.
43. Spector, A., L. Thorgrimsen, B. Woods, L. Royan, S. Davies, M. Butterworth, and M. Orrell, Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia: randomised controlled trial. Br J Psychiatry, 2003;183:248-254.
44. Salvioli, G., P. Ventura, and J.M. Pradelli, Impact of nutrition on cognition and affectivity in the elderly: A review. Arch Gerontol Geriatr, 1998;Suppl 5:459-468.
45. Rogers, J., S. Webster, L.F. Lue, L. Brachova, W.H. Civin, M. Emmerling, B. Shivers, D. Walker, and P. McGeer, Inflammation and Alzheimer's disease pathogenesis. Neurobiol Aging, 1996;17:681-686.
46. Kalaria, R.N., The role of cerebral ischemia in Alzheimer's disease. Neurobiol Aging, 2000;21:321-330.
47. Braekhus, A. and K. Engedal, [Vascular dementia--an ill-defined concept]. Tidsskr Nor Laegeforen, 2004;124:1097-1099.
Hayden, M. Norton, P.V. Rabins, R.C. Green, K.A. Welsh-Bohmer, J.C. Breitner, R. Munger, and C.G. Lyketsos, Vascular factors predict rate of progression in Alzheimer disease. Neurology, 2007;69:1850-1858.
49. Andin, U., Vascular dementia, classification and clinical correlates, in Department of Clinical Sciences Lund University, Sweden. 2007, Lunds universitet: Lund. Thesis.
50. McCaddon, A., G. Davies, P. Hudson, S. Tandy, and H. Cattell, Total serum homocysteine in senile dementia of Alzheimer type. Int J Geriatr Psychiatry, 1998;13:235-239.
51. Smith, A.D., The worldwide challenge of the dementias: a role for B vitamins and homocysteine? Food Nutr Bull, 2008;29:S143-172.
52. Mari, D., L. Parnetti, R. Coppola, B. Bottasso, G.P. Reboldi, U. Senin, and P.M. Mannucci, Hemostasis abnormalities in patients with vascular dementia and Alzheimer's disease. Thromb Haemost, 1996;75:216-218. 53. Bots, M.L., M.M. Breteler, F. van Kooten, F. Haverkate, P. Meijer, P.J.
Koudstaal, D.E. Grobbee, and C. Kluft, Coagulation and fibrinolysis markers and risk of dementia. The Dutch Vascular Factors in Dementia Study. Haemostasis, 1998;28:216-222.
54. Stott, D.J., E. Spilg, A.M. Campbell, A. Rumley, M.A. Mansoor, and G.D. Lowe, Haemostasis in ischaemic stroke and vascular dementia. Blood Coagul Fibrinolysis, 2001;12:651-657.
55. Butz, L.W. and V. Du Vigneaud, The formation of a homologue of cysteine by the decomposition of methionine with sulphuric acid. Journal of Biological Chemistry, 1932;99:135-142.
56. Carson, N.A. and D.W. Neill, Metabolic abnormalities detected in a survey of mentally backward individuals in Northern Ireland. Arch Dis Child, 1962;37:505-513.
57. Gerritsen, T., J.G. Vaughn, and H.A. Waisman, The identification of homocystine in the urine. Biochem Biophys Res Commun, 1962;9:493- 496.
58. Mudd, S.H., J.D. Finkelstein, F. Irreverre, and L. Laster, Homocystinuria: An Enzymatic Defect. Science, 1964;143:1443-1445.
59. Strauss, K.A., D.H. Morton, E.G. Puffenberger, C. Hendrickson, D.L. Robinson, C. Wagner, S.P. Stabler, R.H. Allen, G. Chwatko, H. Jakubowski, M.D. Niculescu, and S.H. Mudd, Prevention of brain disease from severe 5,10-methylenetetrahydrofolate reductase deficiency. Mol Genet Metab, 2007;91:165-175.
60. Frosst, P., H.J. Blom, R. Milos, P. Goyette, C.A. Sheppard, R.G. Matthews, G.J. Boers, M. den Heijer, L.A. Kluijtmans, L.P. van den Heuvel, and et al., A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet, 1995;10:111-113.
61. McCully, K.S., Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol, 1969;56:111-128. 62. McCully, K.S. and R.B. Wilson, Homocysteine theory of arteriosclerosis.
Atherosclerosis, 1975;22:215-227.
63. Wilcken, D.E. and B. Wilcken, The pathogenesis of coronary artery disease. A possible role for methionine metabolism. J Clin Invest, 1976;57:1079-1082.
64. Wilcken, D.E. and V.J. Gupta, Sulphr containing amino acids in chronic renal failure with particular reference to homocystine and cysteine- homocysteine mixed disulphide. Eur J Clin Invest, 1979;9:301-307. 65. Hvas, A.M., J. Ellegaard, and E. Nexø, Increased plasma methylmalonic
acid level does not predict clinical manifestations of vitamin B12 deficiency. Arch Intern Med, 2001;161:1534-1541.
66. Brattström, L.E., J.E. Hardebo, and B.L. Hultberg, Moderate homocysteinemia--a possible risk factor for arteriosclerotic cerebrovascular disease. Stroke, 1984;15:1012-1016.
67. Vollset, S.E., H. Refsum, A. Tverdal, O. Nygård, J.E. Nordrehaug, G.S. Tell, and P.M. Ueland, Plasma total homocysteine and cardiovascular and noncardiovascular mortality: the Hordaland Homocysteine Study. Am J Clin Nutr, 2001;74:130-136.
68. Scott, J.M., A.M. Molloy, D.G. Kennedy, S. Kennedy, and D.G. Weir, Effects of the disruption of transmethylation in the central nervous system: an animal model. Acta Neurologica Scandinavica. Supplementum, 1994;154:27-31.
69. Steenge, G.R., P. Verhoef, and M.B. Katan, Betaine supplementation lowers plasma homocysteine in healthy men and women. J Nutr, 2003;133:1291-1295.
70. Molloy, A.M. and D.G. Weir, Homocysteine and the nervous system. In: Homocysteine in health and disease, ed. R. Carmel and D.W. Jacobsen. 2001, Cambridge University Press: Cambridge. 183-197.
71. McCully, K.S., Homocysteine and vascular disease. Nat Med, 1996;2:386- 389.
72. Ueland, P.M., H. Refsum, and J. Schneede, Determinants of plasma homocysteine. In: Homocysteine and vascular disease, ed. K. Robinson. 2000, Kluwer Academic Publishers: Dordrecht. 59-84.
73. Vermaak, W.J., J.B. Ubbink, H.C. Barnard, G.M. Potgieter, H. van Jaarsveld, and A.J. Groenewald, Vitamin B-6 nutrition status and cigarette smoking. Am J Clin Nutr, 1990;51:1058-1061.
74. Yang, Q., L.D. Botto, J.D. Erickson, R.J. Berry, C. Sambell, H. Johansen, and J.M. Friedman, Improvement in stroke mortality in Canada and the United States, 1990 to 2002. Circulation, 2006;113:1335-1343.
75. Toole, J.F., M.R. Malinow, L.E. Chambless, J.D. Spence, L.C. Pettigrew, V.J. Howard, E.G. Sides, C.H. Wang, and M. Stampfer, Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA, 2004;291:565-575. 76. Bönaa, K.H., I. Njolstad, P.M. Ueland, H. Schirmer, A. Tverdal, T.
Steigen, H. Wang, J.E. Nordrehaug, E. Arnesen, and K. Rasmussen, Homocysteine Lowering and Cardiovascular Events after Acute Myocardial Infarction. N Engl J Med, 2006;354:1578-1588.
77. Lonn, E., S. Yusuf, M.J. Arnold, P. Sheridan, J. Pogue, M. Micks, M.J. McQueen, J. Probstfield, G. Fodor, C. Held, and J. Genest, Jr., Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med, 2006;354:1567-1577.
78. Goodwin, J.S., J.M. Goodwin, and P.J. Garry, Association between nutritional status and cognitive functioning in a healthy elderly
population. JAMA, 1983;249:2917-2921.
79. Lindenbaum, J., E.B. Healton, D.G. Savage, J.C. Brust, T.J. Garrett, E.R. Podell, P.D. Marcell, S.P. Stabler, and R.H. Allen, Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. N Engl J Med, 1988;318:1720-1728.
80. Nilsson, K., L. Gustafson, R. Fäldt, A. Andersson, L. Brattström, A. Lindgren, B. Israelsson, and B. Hultberg, Hyperhomocysteinaemia - a common finding in a psychogeriatric population. Eur J Clin Invest, 1996;26:853-859.
81. Clarke, R., A.D. Smith, K.A. Jobst, H. Refsum, L. Sutton, and P.M. Ueland, Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol, 1998;55:1449-1455.
82. Ravaglia, G., P. Forti, F. Maioli, A. Muscari, L. Sacchetti, G. Arnone, V. Nativio, T. Talerico, and E. Mariani, Homocysteine and cognitive function in healthy elderly community dwellers in Italy. Am J Clin Nutr, 2003;77:668-673.
83. Becker, A., S. Vezmar, M. Linnebank, H. Pels, U. Bode, U. Schlegel, and U. Jaehde, Marked elevation in homocysteine and homocysteine sulfinic acid in the cerebrospinal fluid of lymphoma patients receiving intensive treatment with methotrexate. Int J Clin Pharmacol Ther, 2007;45:504- 515.
84. Sun, Y., C.J. Lu, K.L. Chien, S.T. Chen, and R.C. Chen, Efficacy of multivitamin supplementation containing vitamins B6 and B12 and folic acid as adjunctive treatment with a cholinesterase inhibitor in Alzheimer's disease: a 26-week, randomized, double-blind, placebo-controlled study in Taiwanese patients. Clin Ther, 2007;29:2204-2214.
85. Aisen, P.S., L.S. Schneider, M. Sano, R. Diaz-Arrastia, C.H. van Dyck, M.F. Weiner, T. Bottiglieri, S. Jin, K.T. Stokes, R.G. Thomas, and L.J. Thal, High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA, 2008;300:1774- 1783.
86. Hoffbrand, A.V. and D.G. Weir, The history of folic acid. Br J Haematol, 2001;113:579-589.
87. Molloy, A.M., J.L. Mills, P.N. Kirke, A.S. Whitehead, D.G. Weir, and J.M. Scott, Whole-blood folate values in subjects with different methylenetetrahydrofolate reductase genotypes: differences between the radioassay and microbiological assays. Clin Chem, 1998;44:186-188. 88. Herbert, V. and R. Zalusky, Selective concentration of folic acid activity in
cerebro-spinal fluid. Federation Proceedings, 1961;20:453 (Abstract). 89. Wells, D.G. and H.J. Casey, Lactobacillus casei C.S.F. folate activity. Br
Med J, 1967;3:834-837.
90. Alperin, J.B. and M.E. Haggard, Cerebrospinal fluid folate (CFA) and the blood brain barrier. Clin Res, 1970;18:40.
91. Reynolds, E.H., B.B. Gallagher, R.H. Mattson, M. Bowers, and A.L. Johnson, Relationship between serum and cerebrospinal fluid folate. Nature, 1972;240:155-157.
92. Wollack, J.B., B. Makori, S. Ahlawat, R. Koneru, S.C. Picinich, A. Smith, I.D. Goldman, A. Qiu, P.D. Cole, J. Glod, and B. Kamen, Characterization of folate uptake by choroid plexus epithelial cells in a rat primary culture
model. J Neurochem, 2008;104:1494-1503.
93. Herbert, V. and R. Zalusky, Interrelations of vitamin B12 and folic acid metabolism: folic acid clearance studies. J Clin Invest, 1962;41:1263-1276. 94. Rothberg, K.G., Y.S. Ying, J.F. Kolhouse, B.A. Kamen, and R.G.
Anderson, The glycophospholipid-linked folate receptor internalizes folate without entering the clathrin-coated pit endocytic pathway. J Cell Biol, 1990;110:637-649.
95. Qiu, A., M. Jansen, A. Sakaris, S.H. Min, S. Chattopadhyay, E. Tsai, C. Sandoval, R. Zhao, M.H. Akabas, and I.D. Goldman, Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell, 2006;127:917-928.
96. Minot, C.R. and W.P. Murphy, Treatment of pernicious anaemia by special diet. J Am Med Assoc, 1926;87:470-476.
97. Rickes, E.L., N.G. Brink, F.R. Koniuszy, T.R. Wood, and K. Folkers, Crystalline Vitamin B12. Science, 1948;107:396-397.
98. Smulders, Y.M., D.E. Smith, R.M. Kok, T. Teerlink, D.W. Swinkels, C.D. Stehouwer, and C. Jakobs, Cellular folate vitamer distribution during and after correction of vitamin B12 deficiency: a case for the methylfolate trap. Br J Haematol, 2006;132:623-629.
99. Strachan, R.W. and J.G. Henderson, Psychiatric syndromes due to avitaminosis B 12 with normal blood and marrow. Q J Med, 1965;34:303-317.
100. Sandyk, R. and G.I. Awerbuch, Vitamin B12 and its relationship to age of onset of multiple sclerosis. Int J Neurosci, 1993;71:93-99.
101. Regland, B., L. Abrahamsson, K. Blennow, C.G. Gottfries, and A. Wallin, Vitamin B12 in CSF: reduced CSF/serum B12 ratio in demented men. Acta Neurologica Scandinavica, 1992;85:276-281.
102. György, P., Vitamin B2 and the pellagra-like dermatitis in rats. Nature, 1934;133:498.
103. Korbut, R., A. Dembinska-Kiec, and R.J. Gryglewski, Fibrinolysis and atherosclerosis. In: Fibrinolysis and the central nervous system, ed. R. Sawaya. 1990, Hanley & Belfus, Inc: Philadelpia. 86-94.
104. Sundell, I.B., T.K. Nilsson, M. Rånby, G. Hallmans, and G. Hellsten, Fibrinolytic variables are related to age, sex, blood pressure, and body build measurements: a cross-sectional study in Norsjo, Sweden. J Clin Epidemiol, 1989;42:719-723.
105. Fermo, I., S. Vigano' D'Angelo, R. Paroni, G. Mazzola, G. Calori, and A. D'Angelo, Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann Intern Med, 1995;123:747-753.
106. Stamler, J.S., J.A. Osborne, O. Jaraki, L.E. Rabbani, M. Mullins, D. Singel, and J. Loscalzo, Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest, 1993;91:308-318.
107. D'Angelo, A. and J. Selhub, Homocysteine and thrombotic disease. Blood, 1997;90:1-11.
108. Diagnostic and statistical manual of mental disorders, 3rd ed. Revised. (DSM-III-R), in. 1987, Washington DC: American Psychiatric Association. 109. McKhann, G., D. Drachman, M. Folstein, R. Katzman, D. Price, and E.M.
Stadlan, Clinical diagnosis of Alzheimer's disease: report of the NINCDS- ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology, 1984;34:939-944.
110. Nilsson, M., B. Norberg, J. Hultdin, H. Sandstrom, G. Westman, and J. Lökk, Medical intelligence in Sweden. Vitamin B12: oral compared with parenteral? Postgrad Med J, 2005;81:191-193.
111. Folstein, M.F., S.E. Folstein, and P.R. McHugh, "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res, 1975;12:189-198.
112. Diagnostic and statistical manual of mental disorders, 4th ed. (DSM-IV), in. 1994, Washington DC: American Psychiatric Association.
113. The ICD-10 Classification of Mental and Behavioural Disorders. Clinical descriptions and diagnostic guidelines, in. 1997, Geneva: World Health Organization.
114. Erkinjuntti, T., Clinical criteria for vascular dementia: the NINDS-AIREN criteria. Dementia, 1994;5:189-192.
115. Shulman, K.I., Clock-drawing: is it the ideal cognitive screening test? Int J Geriatr Psychiatry, 2000;15:548-561.
116. Thalmann, B., R. Spiegel, H. Stähelin, B. Brubacher, D. Ermini- Fünfschilling, S. Bläsi, and A.U. Monsch, Dementia Screening in General Practice: Optimised Scoring for the Clock Drawing Test. Barin Aging, 2002;2:36-43.
117. Dehlin, O. and Å. Rundgren, Läkemedelsbehandling av äldre, in. Geriatrik. Vol. 2:1. 2007: Studentlitteratur. 67-75.
118. Hughes, C.P., L. Berg, W.L. Danziger, L.A. Coben, and R.L. Martin, A new clinical scale for the staging of dementia. Br J Psychiatry, 1982;140:566-572.
119. Spector, R., Vitamin homeostasis in the central nervous system. N Engl J Med, 1977;296:1393-1398.
120. Tricco, A.C., J. Tetzlaff, M. Sampson, D. Fergusson, E. Cogo, T. Horsley, and D. Moher, Few systematic reviews exist documenting the extent of bias: a systematic review. J Clin Epidemiol, 2008;61:422-434.
121. Lanzkowsky, P., Congenital malabsorption of folate. Am J Med, 1970;48:580-583.
122. Ramaekers, V.T., S.P. Rothenberg, J.M. Sequeira, T. Opladen, N. Blau, E.V. Quadros, and J. Selhub, Autoantibodies to folate receptors in the cerebral folate deficiency syndrome. N Engl J Med, 2005;352:1985-1991. 123. Berrocal-Zaragoza, M.I., J.D. Fernandez-Ballart, M.M. Murphy, P.
Cavalle-Busquets, J.M. Sequeira, and E.V. Quadros, Association between blocking folate receptor autoantibodies and subfertility. Fertil Steril,